Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider

Detalles Bibliográficos
Autores principales: Honore, Patrick M., Barreto Gutierrez, Leonel, Kugener, Luc, Redant, Sebastien, Attou, Rachid, Gallerani, Andrea, De Bels, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545152/
https://www.ncbi.nlm.nih.gov/pubmed/33036639
http://dx.doi.org/10.1186/s13054-020-03294-7
_version_ 1783591975322124288
author Honore, Patrick M.
Barreto Gutierrez, Leonel
Kugener, Luc
Redant, Sebastien
Attou, Rachid
Gallerani, Andrea
De Bels, David
author_facet Honore, Patrick M.
Barreto Gutierrez, Leonel
Kugener, Luc
Redant, Sebastien
Attou, Rachid
Gallerani, Andrea
De Bels, David
author_sort Honore, Patrick M.
collection PubMed
description
format Online
Article
Text
id pubmed-7545152
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75451522020-10-09 Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider Honore, Patrick M. Barreto Gutierrez, Leonel Kugener, Luc Redant, Sebastien Attou, Rachid Gallerani, Andrea De Bels, David Crit Care Letter BioMed Central 2020-10-09 /pmc/articles/PMC7545152/ /pubmed/33036639 http://dx.doi.org/10.1186/s13054-020-03294-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter
Honore, Patrick M.
Barreto Gutierrez, Leonel
Kugener, Luc
Redant, Sebastien
Attou, Rachid
Gallerani, Andrea
De Bels, David
Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider
title Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider
title_full Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider
title_fullStr Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider
title_full_unstemmed Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider
title_short Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider
title_sort infliximab can reduce mortality from 35 to 14% in critically ill patients with covid-19: perhaps some potential confounders to consider
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545152/
https://www.ncbi.nlm.nih.gov/pubmed/33036639
http://dx.doi.org/10.1186/s13054-020-03294-7
work_keys_str_mv AT honorepatrickm infliximabcanreducemortalityfrom35to14incriticallyillpatientswithcovid19perhapssomepotentialconfounderstoconsider
AT barretogutierrezleonel infliximabcanreducemortalityfrom35to14incriticallyillpatientswithcovid19perhapssomepotentialconfounderstoconsider
AT kugenerluc infliximabcanreducemortalityfrom35to14incriticallyillpatientswithcovid19perhapssomepotentialconfounderstoconsider
AT redantsebastien infliximabcanreducemortalityfrom35to14incriticallyillpatientswithcovid19perhapssomepotentialconfounderstoconsider
AT attourachid infliximabcanreducemortalityfrom35to14incriticallyillpatientswithcovid19perhapssomepotentialconfounderstoconsider
AT galleraniandrea infliximabcanreducemortalityfrom35to14incriticallyillpatientswithcovid19perhapssomepotentialconfounderstoconsider
AT debelsdavid infliximabcanreducemortalityfrom35to14incriticallyillpatientswithcovid19perhapssomepotentialconfounderstoconsider

Ejemplares similares